Xenotropic murine leukemia virus-related virus is susceptible to AZT

Virology

Volumn 397, Issue 1, 2010, Pages 1-6

  Sakuma, Ryuta ^a   Sakuma, Toshie ^a   Ohmine, Seiga ^a   Silverman, Robert H ^b   Ikeda, Yasuhiro ^a  

^a MAYO CLINIC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

118 D 24; 3TC; AZT; D4T; Efavirenz; Indinavir; Ritonavir; Saquinavir; Tenofovir; XMRV

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION PREVENTION; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; SEQUENCE HOMOLOGY; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; XENOTROPIC VIRUS;

AMINO ACID MOTIFS; ANTI-RETROVIRAL AGENTS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PROSTATE; RETROVIRIDAE; REVERSE TRANSCRIPTION; RNA-DIRECTED DNA POLYMERASE; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL PROTEINS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; XENOTROPIC MURINE LEUKEMIA VIRUS;

EID: 74249109753     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.013     Document Type: Article

References (52)

1. Armanios M., Chen J.L., Chang Y.P., Brodsky R.A., Hawkins A., Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A., and Greider C.W. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc. Natl. Acad. Sci. U. S. A. 102 44 (2005) 15960-15964
2. Battini J.L., Rasko J.E., and Miller A.D. A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proc. Natl. Acad. Sci. U. S. A. 96 4 (1999) 1385-1390
3. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75 (2001) 4832-4842
4. Boyer P.L., Gao H.Q., Clark P.K., Sarafianos S.G., Arnold E., and Hughes S.H. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. J. Virol. 75 (2001) 6321-6328
5. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. 76 (2002) 9143-9151
6. Canard B., Chowdhury K., Sarfati R., Doublie S., and Richardson C.C. The motif D loop of human immunodeficiency virus type 1 reverse transcriptase is critical for nucleoside 5′-triphosphate selectivity. J. Biol. Chem. 274 50 (1999) 35768-35776
7. Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., and Witte J.S. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32 4 (2002) 581-583
8. Coates J.A., Cammack N., Jenkinson H.J., Mutton I.M., Pearson B.A., Storer R., Cameron J.M., and Penn C.R. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents. Chemother. 36 1 (1992) 202-205
9. Dong B., Kim S., Hong S., Das Gupta J., Malathi K., Klein E.A., Ganem D., Derisi J.L., Chow S.A., and Silverman R.H. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. U. S. A. 104 5 (2007) 1655-1660
10. Fan H. Leukemogenesis by Moloney murine leukemia virus: a multistep process. Trends Microbiol. 5 2 (1997) 74-82
11. Gao Q., Gu Z.X., Parniak M.A., Li X.G., and Wainberg M.A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66 1 (1992) 12-19
12. Gu Z., Fletcher R.S., Arts E.J., Wainberg M.A., and Parniak M.A. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′, 3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269 45 (1994) 28118-28122
13. Hong S., Klein E.A., Das Gupta J., Hanke K., Weight C.J., Nguyen C., Gaughan C., Kim K.A., Bannert N., Kirchhoff F., Munch J., and Silverman R.H. Fibrils of prostate acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J. Virol. 83 14 (2009) 6995-7003
14. Kawakami T.G., Theilen G.H., Dungworth D.L., Munn R.J., and Beall S.G. "C"-type viral particles in plasma of cats with feline leukemia. Science 158 804 (1967) 1049-1050
15. Kawakami T.G., Huff S.D., Buckley P.M., Dungworth D.L., Synder S.P., and Gilden R.V. C-type virus associated with gibbon lymphosarcoma. Nat. New Biol. 235 58 (1972) 170-171
16. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U. S. A. 92 7 (1995) 2484-2488
17. Knouf E.C., Metzger M.J., Mitchell P.S., Arroyo J.D., Chevillet J.R., Tewari M., and Miller A.D. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J. Virol. 83 14 (2009) 7353-7356
18. Lacey S.F., and Larder B.A. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance. J. Virol. 68 5 (1994) 3421-3424
19. Larder B.A., Kemp S.D., and Purifoy D.J. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. U. S. A. 86 13 (1989) 4803-4807
20. Lopez-Galindez C., Rojas J.M., Najera R., Richman D.D., and Perucho M. Characterization of genetic variation and 3′-azido-3′-deoxythymidine-resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method. Proc. Natl. Acad. Sci. U. S. A. 88 10 (1991) 4280-4284
21. Lund A.H., Turner G., Trubetskoy A., Verhoeven E., Wientjens E., Hulsman D., Russell R., DePinho R.A., Lenz J., and van Lohuizen M. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 32 1 (2002) 160-165
22. Martin J.A., Mobberley M.A., Redshaw S., Burke A., Tyms A.S., and Ryder T.A. The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. Biochem. Biophys. Res. Commun. 176 1 (1991) 180-188
23. Masquelier B., Tamalet C., Montes B., Descamps D., Peytavin G., Bocket L., Wirden M., Izopet J., Schneider V., Ferre V., Ruffault A., Palmer P., Trylesinski A., Miller M., Brun-Vezinet F., and Costagliola D. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir. Ther. 9 3 (2004) 315-323
24. Matamoros T., Franco S., Vazquez-Alvarez B.M., Mas A., Martinez M.A., and Menendez-Arias L. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 279 23 (2004) 24569-24577
25. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.K., Eckner K., Hattox S., Adams J., et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250 4986 (1990) 1411-1413
26. Mo Y., Gan Y., Song S., Johnston J., Xiao X., Wientjes M.G., and Au J.L. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 63 3 (2003) 579-585
27. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., and Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2 7 (1996) 760-766
28. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N. Engl. J. Med. 349 4 (2003) 366-381
29. Nitanda T., Wang X., Kumamoto H., Haraguchi K., Tanaka H., Cheng Y.C., and Baba M. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49 8 (2005) 3355-3360
30. Noser J.A., Towers G.J., Sakuma R., Dumont J.M., Collins M.K., and Ikeda Y. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J. Virol. 80 15 (2006) 7769-7774
31. Peters G., Brookes S., Smith R., and Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 33 2 (1983) 369-377
32. Powell S.K., Artlip M., Kaloss M., Brazinski S., Lyons R., McGarrity G.J., and Otto E. Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells. J. Virol. 73 (1999) 8813-8816
33. Qari S.H., Magre S., Garcia-Lerma J.G., Hussain A.I., Takeuchi Y., Patience C., Weiss R.A., and Heneine W. Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. J. Virol. 75 2 (2001) 1048-1053
34. Quan Y., Motakis D., Buckheit Jr. R., Xu Z.Q., Flavin M.T., Parniak M.A., and Wainberg M.A. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antivir. Ther. 4 4 (1999) 203-209
35. Rask-Nielsen R. Evidence of murine, virus-induced, paraprotein-producing leukaemia and its relation to other virus-induced leukaemias. Nature 200 (1963) 440 PASSIM
36. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., and Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8 10 (2000) 1089-1094
37. Ruprecht R.M., O'Brien L.G., Rossoni L.D., and Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 323 6087 (1986) 467-469
38. Sarafianos S.G., Clark Jr. A.D., Das K., Tuske S., Birktoft J.J., Ilankumaran P., Ramesha A.R., Sayer J.M., Jerina D.M., Boyer P.L., Hughes S.H., and Arnold E. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21 (2002) 6614-6624
39. Seiki M., Eddy R., Shows T.B., and Yoshida M. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 309 5969 (1984) 640-642
40. Sharpe A.H., Hunter J.J., Ruprecht R.M., and Jaenisch R. Maternal transmission of retroviral disease: transgenic mice as a rapid test system for evaluating perinatal and transplacental antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 85 24 (1988) 9792-9796
41. Sheiness D., Bister K., Moscovici C., Fanshier L., Gonda T., and Bishop J.M. Avian retroviruses that cause carcinoma and leukemia: identification of nucleotide sequences associated with pathogenicity. J. Virol. 33 3 (1980) 962-968
42. Shirasaka T., Kavlick M.F., Ueno T., Gao W.Y., Kojima E., Alcaide M.L., Chokekijchai S., Roy B.M., Arnold E., Yarchoan R., et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 92 6 (1995) 2398-2402
43. Simard J., Dumont M., Soucy P., and Labrie F. Perspective: prostate cancer susceptibility genes. Endocrinology 143 6 (2002) 2029-2040
44. Steffen D. Proviruses are adjacent to c-myc in some murine leukemia virus-induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 81 7 (1984) 2097-2101
45. Strahl C., and Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16 1 (1996) 53-65
46. Tanaka A., Takahashi C., Yamaoka S., Nosaka T., Maki M., and Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc. Natl. Acad. Sci. U. S. A. 87 3 (1990) 1071-1075
47. Tsai C.C., Follis K.E., Sabo A., Beck T.W., Grant R.F., Bischofberger N., Benveniste R.E., and Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 5239 (1995) 1197-1199
48. Urisman A., Molinaro R.J., Fischer N., Plummer S.J., Casey G., Klein E.A., Malathi K., Magi-Galluzzi C., Tubbs R.R., Ganem D., Silverman R.H., and DeRisi J.L. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2 3 (2006) e25
49. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U. S. A. 91 9 (1994) 4096-4100
50. White K.L., Chen J.M., Margot N.A., Wrin T., Petropoulos C.J., Naeger L.K., Swaminathan S., and Miller M.D. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 48 3 (2004) 992-1003
51. Wootton S.K., Halbert C.L., and Miller A.D. Sheep retrovirus structural protein induces lung tumours. Nature 434 7035 (2005) 904-907
52. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S., et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39 12 (1995) 2602-2605